Tag Archives: Drug

New cancer drug delivery system could be 'transformational'

New cancer drug delivery system could be 'transformational'
In a mouse study published this week, the nanotechnology-based strategy destroyed a particularly lethal type of breast cancer after it reached the lung, a stage of the disease considered almost untreatable. The team hopes to test the strategy on …
Read more on Houston Chronicle

Nanoscale rotor, gripper push DNA origami to new limits
Another recent paper, in Nature Nanotechnology, reported a hinged molecular manipulator, also made from DNA. These are just the latest steps in a campaign to transform so-called "DNA origami" into an industrially useful, commercially viable technology.
Read more on Science Daily

Dubai Takes Innovation to the Sports Arena With World Future Sports Games in
Dubai today announced that it will organize World Future Sports Games in December 2017 as the first initiative of its kind in the world featuring innovation and futuristic technology based sports competitions. The World Future Sports Games was unveiled …
Read more on PR Newswire (press release)

The science of watching paint dry; new nanotech research could improve
Date: March 18, 2016; Source: University of Surrey; Summary: New research has described a new physical mechanism that separates particles according to their size during the drying of wet coatings. The discovery could help improve the performance of a …
Read more on Science Daily

Nanobiotix and BiotechCorp Announce Initial Focus of Their Collaboration: P-O-C Diagnostics and Drug Delivery Systems for Tropical Diseases, Such as Malaria


PARIS (PRWEB) September 24, 2008

Malaria is an illness that can be transferred to individuals of any ages through the bites of contaminated mosquitoes. Roughly 40 % of the world’s population is at danger of malaria. Every year, more than 500 million people worldwide become badly ill with malaria. Early medical diagnosis and efficient treatment of malaria condition will reduce its period and prevent the development of complications and the wonderful majority of fatalities from malaria.

.”We are happy to be the first partner of Nanobiotix outside of its cancer focus,” stated BiotechCorp’s CEO Datuk Iskandar Mizal Mahmood. “We securely believe that the chance to help save millions of lives is in reality a near-term possibility as an outcome of this collaboration between BiotechCorp and Nanobiotix. Additionally, this collaboration is a substantial testament to the readiness of the Malaysian biotechnology industry in commercializing science to market, whilst addressing difficulties in our part of the field.”

.”BiotechCorp provides Nanobiotix a direct path through Asia,” stated Laurent L vy, Ph.D., Head of state and Chief Executive Officer of Nanobiotix and Co-President of the French Technology Platform on Nanomedicine (FTPN). “Certainly, their strategic place in the heart of Asia, in addition to Malaysia’s pro-business government, political security, and cost-effective base for doing company are amongst the numerous benefit reasons we have actually decided to partner with BiotechCorp.”

. Dr. L vy will be a keynote speaker on nanotechnology at “Bio Malaysia 2008″the Malaysian worldwide biotechnology occasion that will occur from October 7-9 in Kuala Lumpur, Malaysia. For additional details about this event, please browse through http://www.biomalaysia.com.my.

. ABOUT BIOTECHCORP

. BiotechCorp is the lead development agency for the biotech industry in Malaysia and serves as a main contact point supplying support, facilitation and advisory services for life sciences business in Malaysia. Considering that its establishment in 2005, BiotechCorp has actually played a key duty in developing the biotech company in Malaysia. To this day, BiotechCorp has actually facilitated the development of 71 BioNexus-status business in Malaysia, with total approved financial investment of US$ 400 million (RM1.3 billion). BioNexus-status companies are worldwide and Malaysian biotech business that get fiscal incentives, grants and guarantees administered by BiotechCorp. For additional information, please browse through http://www.biotechcorp.com.my.

. ABOUT NANOBIOTIX

. Nanobiotix is an arising nanomedicine business incorporating remarkable advances in nanotechnology and molecular biology to put together nanoXray an innovation platform that is expected to be turned ‘on’ and ‘off’ outside the body to selectively treat a variety of cancers safely and noninvasively. Use of nanoXray is planned to solve radiation therapy’s greatest disadvantage: destruction of healthy tissue and its subsequent deleterious negative side effects when a high dose of Xray is essential. The core of a nanoXray nanoparticle is a less active and inert substancenot a drugthat can be activated to locally (intratumor) increase the dose of Xray, which is then anticipated to bring about higher effectiveness. After nanoXray nanoparticles collect in the target tissues, a standard X-ray is applied that is intended to produce a neighborhood restorative impact, developed to ruin just the targeted growth cells. This mechanism recommends overall control of the designated restorative result.

.
.
.

. . More Nanomedicine Business Press Releases

Absorption Systems Innovation in Drug Metabolism and Metabolite ID Leads to Patent Application


Exton, PA (PRWEB) Might 31, 2011

Absorption Systems validated its claim as a leader in testing medicines for ADMET (absorption, distribution, metabolism, excretion and toxicity), when the company revealed today that one of its experts, Dr. Igor Mezine, was called a creator on an international patent application submitted by Belgian medicine developer Shire-Movetis NV. The target of the patent application, now offered in the public domain, is using a novel course of chemicals, (1,4)-benzodiazepines, as vasopressin V2 receptor villains. The potential medical indicator of vasopressin receptor villains is the therapy of high blood pressure.

. In a study contracted to Absorption Systems by Movetis NV (since acquired by Shire PLC), Dr. Mezine utilized one of the innovative procedures established by Absorption Systems to produce a book metabolite of a drug candidate. The process, biomimetic oxidation, makes use of a totally artificial system that simulates a few of the enzymatic reactions carried out in the body by specific liver enzymes. The metabolite, which had actually eluded synthesis by conventional medical chemistry, was as pharmacologically active as the moms and dad compound. In subsequent testing by Shire-Movetis, the new molecule was found to be a vasopressin receptor inhibitor.

. Biomimetic oxidation, described in a short article by Dr. Mezine and colleagues in Genetic Engineering and Biotechnology Information (GEN) in 2009, has actually been the basis for various performances at clinical conferences over the past numerous years. It is a sign of Absorption Systems expertise in medicine metabolic process and metabolite identification, as well as the companys capability to address hard concerns with cutting-edge options.

. Patrick Dentinger, president and CEO of Absorption Systems, commented that this application of biomimetic oxidation is simply another example of the development and one-of-a-kind expertise that we offer on our customers ADMET challenges. Sometimes, as in this case, the advantages go beyond exactly what either celebration anticipated.

. About Absorption Systems . Absorption Systems, started in 1996, aids pharmaceutical and clinical gadget companies in determining and getting over ADMET (Absorption, Distribution, Metabolic rate, Excretion and Toxicity) barriers in the development of drugs and clinical gadgets. The business’s goal is to constantly establish ingenious study tools that can be utilized to properly predict human outcomes or to explain unanticipated human results when they occur. The CellPort Technologies platform, a suite of human cell-based test systems for drug transporter characterization, exhibits Absorption Systems’ dedication to advancement and is quickly to be a market standard for in vitro medicine interaction assessment. Absorption Systems has facilities near Philadelphia, PA, and San Diego, CA, and serves customers throughout the world. For info on the company’s thorough agreement services and used study programs, please visit http://www.absorption.com. . ### . .

.
.
.

More Biotechnology News Press Releases

Neumedicines Oncology and Hematology Drug Candidates Featured in BIOWORLD Magazine

Pasadena, CA (PRWEB) June 06, 2011

Neumedicines, an independently held drug discovery and development company concentrated on ingenious protein treatments for the treatment of hematopoietic deficiencies, cancer cells and autoimmune illness, announced today that a profile of the company and its pipeline of oncology and hematology medicine prospects is featured in the most current issue of BioWorld, among the most extensively review publications in the pharma and biotech industries. The article can be acquired at http://www.bioworld.com. . The publication kept in mind that

, Taking opportunity from the failure of others, Neumedicines Inc. is rejuvenating Interleukin-12( IL-12), a biologic as soon as seen as the great hope for cancer cells. The Pasadena, Calif.-based company launched a Phase I safety trial Thursday for its lead candidate, HemaMax, a key regulatory authority of the hematopoietic system. Initially, the trial will enlist about 40 targets, but Neumedicines aims to broaden its safety database to cover up to 500 volunteers from diverse populations. . The article likewise kept in mind: Neumedicines has huge strategies for its lead candidate.

The company is dealing with the protocol for a Stage I cancer cells research with the BEGINNING Center in San Antonio and intends to file an investigational brand-new medicine application in the fall for pancreatic cancer cells. . Dr. Lena Basile, Neumedicines Chief Executive Policeman stated, We are pleased to get acknowledgment from a worldwide biotech publication for our lead pipeline item, HemaMax, that has shown durable and broad hematopoietic recovery in lethally irradiated animal models in addition to in tumor-bearing animals treated with radiation and radiation treatment. . We anticipate the results of our Phase I HemaMax medical trial which we expect by February 2012, Dr. Basile included.

. About BioWorld Today . BioWorld Today, the news source of record for the biotechnology industry, is read by biotechnology specialists worldwide for its powerful, objective information reporting. BioWorld Today is provided by means of e-mail every business morning, and is also found exclusively online at http://www.bioworld.com. The BioWorld online website has actually been globally acknowledged as the most comprehensive resource for strategic biotechnology information and details readily available today. . About Neumedicines Inc. . Neumedicines Inc. is an independently held, early-stage business developing protein therapeutics that take care of unmet clinical and societal

requirements in the fields of oncology, hematology, and immunology. The business lead product prospect, NMIL12-1 (recombinant human interleukin-12; rHuIL-12 ), functions regarding target several pathways of hematopoiesis and innate immunity and is being developed to address an array of clinical indicators. At Neumedicines, we are committed to developing and making best use of the scientific, clinical, and commercial capacity of our item pipeline. . Neumedicines is developing NMIL12-1 under the brand HemaMax as a biodefense radiation clinical countermeasure. NMIL12-1 is also being developed for

indications in hematology/oncology, such as chemotherapy-induced thrombocytopenia. The company operates from its head office and labs in Pasadena, California. . For even more info see: http://www.neumedicines.com . Follow Neumedicines on Twitter @ Neumedicines . This press release contains specific forward-looking

statements connecting to our business. Actual events or outcomes might differ from the expectations set forth herein as an outcome of a variety of

elements, consisting of uncertainties inherent in pre-clinical studies, clinical trials and product development programs. There can be no guarantee that any product in Neumedicines pipeline will be effectively established or manufactured, that outcomes of clinical studies will be encouraging of regulative approvals required to market licensed items, or that any of the forward-looking info offered herein will be shown accurate. . Investor and partnership makes inquiries please contact: Dr. Lena Basile at 626-844-3800 or basile(at )neumedicines(dot) com . Media members please contact: Jeff Richardson at 805-491-8313 or jeff (at) richardsonglobalpr(

dot)com . # # # . . . . .

Antibody Drug Conjugates Market, 2012-2023


Rockville, MD (PRWEB) October 16, 2013

Antibody Medicine Conjugates Market, 2012-2023

. Instead of blasting away at a tumor site, an incision strike is made by securing ADCs onto a target. “This must lead to less damage to the body as the cytotoxic medicines are given targeted cells rather than sent throughout the body,” states Shivani Singh, who wrote a recent report on the ADC market for consultants Roots Analysis. The business anticipates the marketplace might be worth $ 9 billion (5.75 billion) by 2023. Big pharma has been a passionate supporter, hooking up with ADC innovation leaders.

. The heterogeneous mixtures of ADCs position difficulties for production, states Singh, and site-specific conjugation “is quite an appealing way of conference that challenge.” Apart from big pharma and biotechs as innovation providers, she sees a function for contract makers in ADCs, though they do not have the ability to commercially produce ADCs. Singh is positive about the future and says communication in between ADC designers and the FDA is on the up: “The procedure must become smoother, as companies are receiving more assistance from the FDA in the initial stages of development.”

. There is also a shift in the partnership models in between business; the big pharma players had actually utilized technology licensing models to establish ADCs, however “rather than licensing they are now collaborating for product development,” says Singh. Centuries got in into a collaboration with Seattle Genetics to obtain a special license to market Adcetris outside the US and Canada, for example.

.”There are a few drugs in development for non-oncological signs, however from exactly what we discovered they are all in pre-clinical stages,” states Singh.

. Roots Analysis predicted that ADCs of the non-oncological space will follow on from initial successes in cancer cells therapeutics. However for the foreseeable future oncology is where it is at. Roots Analysis ADC report in July looked at the rich pipeline 33 drugs in medical development and predicted a quickening speed ahead. It determined brand-new linker and cytotoxin innovation as strengths, in addition to funding from financial backing companies. Hazards identified included a high failure rate of pipeline drugs and post advertising withdrawals. The reports base sales forecast imagined the total ADC market at $ 370 million in 2013, rising to around $ 9 billion in 2023. Its positive scenario had this at $ 400 million this year, $ 12 billion in 2023. This potential has actually pushed the ADC bandwagon along, with many drugs in preclinical development at business consisting of GSK, Pfizer, Abbott and Roche, in addition to many smaller sized players. Whether ADCs can march from clinical trials into blockbuster condition remains to be seen.

. To get this report:

. Antibody Medicine Conjugates Market, 2012-2023

. Contact: Shauna . 800.298.5699 .

Customerservice(at)marketresearch(dot)com

. Roots Analysis Pvt. Ltd.

. Roots Analysis provides company research and consulting in the pharmaceutical market. Concentrated on providing an informed and impartial view on essential issues facing the market, our study is mainly driven by a comprehensive analysis covering the following criteria:

.-Innovation advancement .-R & d .-Existing market landscape .-Future Commercial potential .-Regulatory concerns .-Regional growth motorists .-Threats and chances

. About MarketResearch.com

. MarketResearch.com is the leading carrier of international market intelligence products and services. With study reports from even more than 720 top consulting and advisory firms, MarketResearch.com offers instant online access to the worlds most considerable database of professional insights on international industries, companies, products, and trends. Moreover, MarketResearch.com s Study Specialists have in-depth knowledge of the publishers and the various kinds of reports in their particular industries and are ready to offer research assistance. For more info, call Cindy Frei at 240.747.3014 or visit http://www.marketresearch.com.

. Follow us on Facebook http://www.facebook.com/marketresearchdotcom.

. Follow us on Twitter http://www.twitter.com/marketresearch_.

. Antibody Drug Conjugates Market, 2012-2023 Tabulation:

. 1. EXECUTIVE SUMMARY . 2. INTRO .

3. ADC THERAPEUTICS: OVERVIEW AND BACKGROUND . 3.1. Chapter Summary . 3.2. Kadcyla Becomes Third ADCs to Reach Market . 3.2.1. Mylotarg (Pfizer) . 3.2.1.1. Mechanism of Activity . 3.2.1.2. Approval and Discontinuation of Mylotarg in the United States . 3.2.1.3. Reasons for Poor Clinical Perks of Mylotarg . 3.2.2. Adcetris (Seattle Genetics/Takeda Oncology Company) . 3.2.3. Kadcyla (Roche/Genentech) . 3.3. Business Active in the ADC Market . 3.3.1. Large Pharmaceutical Business Taking Interest . 3.4. Business Providing ADC Innovation . 3.5. Duty of Endeavor Capitalists . 3.6. Analysis of the Development Pipeline . 3.6.1. Limited Number of Molecules in Late Stage Development . 3.6.2. Cancer is the Leading Indicator, with ADCs Versus Blood Cancer cells Dominating . 3.6.3. Auristatins are one of the most Popular Contaminant Being Studied . 3.6.4. ADC Market by Kind of Linker . 4. ADC MARKET, 2012 – 2023 . 5. Manufacturing of ADCs . 6. PIPELINE AND MARKET ADVANCEMENTS . 7. PROFILES OF LEADING COMPANIES . 8. SWOT Analysis . 9. CONCLUSIONS .

10. APPENDIX 1: TABLES . 11. APPENDIX 2: LIST OF BUSINESS AND ORGANISATIONS

.
.
.

. . More Biotechnology Products Press Releases

Research Reveals Cancer Drug Effectiveness Substantially Advanced


Santa Barbara, Calif. (Vocus) April 9, 2010

Researchers have shown that a peptide (a chain of amino acids) called iRGD aids co-administered drugs penetrate deeply into tumor tissue. The peptide has been shown to substantially enhance remedy efficacy against human breast, prostate and pancreatic cancers in mice, achieving the identical therapeutic impact as a typical dose with 1-third as a lot of the drug. In a transformative paper published right now in the on the web edition of the journal Science , Erkki Ruoslahti, M.D., Ph.D. , distinguished professor at Sanford-Burnham Medical Analysis Institute and founding member of the UC Santa Barbara-Sanford|Burnham Center for Nanomedicine, Kazuki N. Sugahara, M.D., Ph.D., Tambet Teesalu, Ph.D., and fellow researchers at the Center for Nanomedicine and the Cancer Center of Santa Barbara, announced this important advance in cancer therapy.

&#13

Drugs normally have difficulty penetrating tumors beyond a few cell diameters from a blood vessel, said Dr. Ruoslahti. This leaves some tumor cells with a suboptimal dose, rising the danger of both recurrence and drug resistance. The iRGD peptide solves this problem by activating a transport program in tumors that distributes co-injected drugs into the complete tumor and increases drug accumulation in the tumor.

&#13

Dr. Ruoslahti showed in the 1980s that a 3 amino-acid peptide motif (RGDArginine-Glycine-Aspartic Acid) serves as a hugely selective identifier of malignant tissue, bind-ing to distinctive receptors in the vasculature of cancers. The RGD peptides ability to residence to tumors has been employed to style new compounds for cancer diagnosis and treatment.

&#13

The new variant of RGD (iRGDinternalizing RGD) combines the RGD motif with a tissue penetration element called CendR. Like the earlier RGD peptides, iRGD residences to tumors, but exposure of the CendR motif when the iRGD is enzymatically cleaved acti-vates a transport method by way of tumor blood vessel walls into the tumor core. In a paper published in Cancer Cell late last year, the investigation team showed that coupling iRGD to anti-cancer drugs allowed them to penetrate deep into tumors, successfully escalating the activity of the drugs.

&#13

The investigation reported in this most recent Science paper adds a new and important twist to the story: The researchers created the unanticipated discovery that anti-cancer drugs do not need to have to be chemically attached to the iRGD peptide for iRGD to enhance their efficacy. Just co-administering iRGD with a drug enhances the drugs anti-cancer properties. Co-administration could be even a lot more powerful at delivering therapeutic agents inside tumors than conjugating the agents with the peptide. This new paradigm implies that iRGD has the possible to improve the efficacy of currently approved drugs with no creat-ing new chemical entities, which would complicate the path to approval for clinical use.

&#13

In addition to becoming successful against human breast, prostate and pancreatic cancers grown in mice, iRGD can penetrate other tumor kinds and could possibly be utilised to treat most, if not all, strong tumors. The iRGD peptide was also shown to boost the therapeutic effects of a number of sorts of anti-cancer drugs, including a tiny molecule drug, a monoclonal antibody and two nanoparticle drugs. Tumors essentially resistant to a specific drug showed excellent responses when the drug was combined with iRGD, and tumors partially responsive to yet another drug had been eradicated by the combination.

&#13

We are really excited about the prospective of iRGD, and Id like to thank my colleagues, Kazuki Sugahara and Tambet Teesalu in specific, who made this all come about, mentioned Dr. Ruoslahti. These benefits with human tumors in mice are quite promising, but we still have to demonstrate the worth of iRGD in treating cancers in humans.

&#13

The Science paper Co-administration of a Tumor-Penetrating Peptide Enhances the&#13

Efficacy of Cancer Drugs will be obtainable at http://sciencemag.org after 5:00 PM EST

&#13

A video interview with Professor Ruoslahti is obtainable at http://vimeo.com/10780518

&#13

Animation of the science is offered at http://www.sanfordburnham.org/motion pictures/ER_Animation_MOV.mov

&#13

A high-resolution image of the illustration is available at http://www.sanfordburnham.org/img/ER_Vers_Three-eight.5x11_300ppi.jpg

&#13

About Sanford-Burnham Medical Investigation Institute &#13

Sanford-Burnham Medical Analysis Institute (formerly Burnham Institute for Health-related Research) is committed to discovering the basic molecular causes of disease and devising the revolutionary therapies of tomorrow. Sanford-Burnham, with operations in California and Florida, is a single of the fastest-developing analysis institutes in the nation. The Institute ranks among the leading independent analysis institutions nationally for NIH grant funding and among the leading organizations worldwide for its research effect. From 1999 2009, Sanford-Burnham ranked #1 worldwide among all varieties of organiza-tions in the fields of biology and biochemistry for the influence of its study publica-tions, defined by citations per publication, according to the Institute for Scientific In-formation. According to government statistics, Sanford-Burnham ranks #two nationally amongst all organizations in capital efficiency of producing patents, defined by the num-ber of patents issued per grant dollars awarded.

&#13

Sanford-Burnham utilizes a exclusive, collaborative strategy to healthcare research and has established major analysis programs in cancer, neurodegeneration, diabetes, and infec-tious, inflammatory, and childhood diseases. The Institute is especially identified for its world-class capabilities in stem cell study and drug discovery technologies. Sanford-Burnham is a nonprofit public advantage corporation. For a lot more data, please check out http://www.sanfordburnham.org .

&#13

About Engineering and the Sciences at UC Santa Barbara&#13

Engineering and the sciences at UC Santa Barbara are worldwide leaders in bioengineering, nanotechnology, physics, chemical and computational engineering, marine science, ma-terials science, neuroscience, and geography. UCSB boasts five Nobel Laureates (4 in sciences and engineering) and 1 winner of the prestigious international Millennium Technology Prize. Our students, faculty, and staff thrive in a uniquely-effective inter-disciplinary and entrepreneurial culture. Our professors study is among the most cited by their peers, evidence of the significance and relevance of their work. For much more data, please visit Engineering.ucsb.edu and Science.UCSB.edu.

&#13

Media Contacts:&#13

Tony Rairden&#13

UCSB College of Engineering&#13

805-453-0123

&#13

Josh Baxt&#13

Sanford-Burnham Healthcare Study Institute&#13

858-795-5236

&#13

# # #

&#13
&#13
&#13
&#13
&#13

Connected Nanomedicine Cancer Press Releases